• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Identification of peptides for an individualised therapeutic vaccine for chronic hepatitis B

Identification of peptides for an individualised therapeutic vaccine for chronic hepatitis B

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户：limajubo
【摘 要】
：
Background:A therapeutic vaccine for chronic hepatitis B that is individualised to contain only peptides specific to each patients HLA class I genotype should have the lowest risk of side effects,and
【作 者】
：
William Abbott Edward Gane 
【机 构】
：
New Zealand Liver Transplant Unit
【出 处】
：
2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议
【发表日期】
：
2014年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background:A therapeutic vaccine for chronic hepatitis B that is individualised to contain only peptides specific to each patients HLA class I genotype should have the lowest risk of side effects,and allow use of stronger adjuvants to maximize efficacy.
其他文献
Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2
Background:Hepatitis B virus(HBV) is a major cause of liver disease which belongs to the Hepadnaviridae family of enveloped DNA viruses.BST-2/tetherin is an interferon-inducible antiviral protein that
会议
Impaired Antibody-Dependent Cellular Cytotoxicity Activity of Natural Killer Cells in Chronic HBV in
Background:Natural Killer(NK) cells are a key player in the innate immunity towards virus infection.However,NK phenotype and functional characteristics during chronic HBV infection are largely controv
会议
The Influence of Concomitant Nonalcoholic Fatty Liver Disease on Fibrosis Severity in Patients with
Background:To identify the impact of concomitant nonalcoholic fatty liver disease(NAFLD) on the development of hepatic fibrosis in patients with chronic hepatitis B(CHB).
会议
Detailed Structural Quantification of Hepatic Cirrhosis Progression
Background:Details in change of fibrosis structure in progressive cirrhosis is still unavailable.Taking advantage of qFibrosis tool,the present study aims to address this issue for understanding the p
会议
COMPARATIVE STUDY OF TELBIVUDINE AND PEGYLATED INTERFERON α-2a OPTIMIZATION THERAPY FOR E ANTIGEN-PO
Background:Aim To observe and compare the efficacy of telbivudine and pegalated interferon α-2a optimized therapy for E antigen-positive chronic hepatitis B patients.
会议
Low prevalence of Hepatitis B virus infection in patients with autoimmune diseases in a Chinese pati
Background:Hepatitis B is a very common communicable disease in China but the prevalence of hepatitis B virus(HBV) infection in patients with autoimmune diseases is unknown.We retrospectively investig
会议
The effect of complemental Ganshuang granule for improving liver fibrosis markers in patients with c
Background:To observe the ability of Ganshuang granules to improve markers of liver fibrosis when provided as supplemental therapy in patients with chronic hepatitis B(CHB) who achieved complete virol
会议
A NOVEL IMMUNOTHERAPY APPROACH WITH MULTIPLE TUMOR ANTIGENS ACTIVATED AUTOLOGOUS T CELLS IN HBV RELA
Background:Hepatocellular carcinoma(HCC) in China frequently occurs in the patients with chronic hepatitis B virus(HBV) infection.Here we present a novel approach(Smart T) of adoptive immunotherapy to
会议
ESTABLISHMENT AND VALIDATION OF ALPH-Q SCORE TO PREDICT MORTALITY RISK IN PATIENTS WITH ACUTE-ON-CHR
Background:There are no strong and powerful models in predicting the outcome of acute-on-chronic hepatitis B liver failure(ACHBLF).Here,we aimed to establish and validate a new prognostic score,named
会议
The diagnostic evaluation to the noninvasive diagnostic of HBV-related cirrhosis with the lantent cl
Background:There are many ways of diagnosis for the HBV-relative cirrhosis,especially,the noninvasive diagnosis,which had been widely used.Before these tests are applied to the clinic,which should be
会议